Evidence map›Paper›PMID 34244158›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Genetic Analysis of Functional Rare Germline Variants across Nine Cancer Types from an Electronic Health Record Linked Biobank.

Manu Shivakumar, Jason E Miller, Venkata Ramesh Dasari, Yanfei Zhang, Ming Ta Michael Lee, David J Carey, Radhika Gogoi, Dokyoon Kim, DiscovEHR collaboration

Open access · bronzeAbstract readValidation Study
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Manu ShivakumarBiomedical & Translational Informatics Institute, Geisinger, Danville, Pennsylvania.
Jason E MillerDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-1835-3512
Venkata Ramesh DasariWeis Center for Research, Geisinger Clinic, Danville, Pennsylvania.
Yanfei ZhangGenomic Medicine Institute, Geisinger, Danville, Pennsylvania.ORCID 0000-0002-9222-7725
Ming Ta Michael LeeGenomic Medicine Institute, Geisinger, Danville, Pennsylvania.
David J CareyDepartment of Molecular and Functional Genomics, Geisinger, Danville, Pennsylvania.
Radhika GogoiWeis Center for Research, Geisinger Clinic, Danville, Pennsylvania. dokyoon.kim@pennmedicine.upenn.edu radhikagogoi@wayne.edu.
Dokyoon Kim
DiscovEHR collaboration
Geisinger Medical Center · USGeisinger Neuroscience Institute · USUniversity City Science Center · US

Funding

Postdoctoral Training Program in Genomic MedicineT32HG009495 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI Katherine L. Nathanson, Bogdan Pasaniuc · 2017 to 2026
$4.2M
Unravelling genetic basis of comorbidity using EHR-linked biobank dataR01GM138597 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI KIM, DOKYOON · 2020 to 2023
$2.2M
Integrating Neuroimaging, Multi-omics, and Clinical Data in Complex DiseaseR01LM012535 · NLM · INDIANA UNIVERSITY INDIANAPOLIS · PI NHO, KWANGSIK TIMOTHY · 2017 to 2021
$1.7M
NHGRI NIH HHS T32 HG009495NIGMS NIH HHS R01 GM138597NLM NIH HHS R01 LM012535
6 · The paper itself

Abstract

backgroundRare variants play an essential role in the etiology of cancer. In this study, we aim to characterize rare germline variants that impact the risk of cancer.

methodsWe performed a genome-wide rare variant analysis using germline whole exome sequencing (WES) data derived from the Geisinger MyCode initiative to discover cancer predisposition variants. The case-control association analysis was conducted by binning variants in 5,538 patients with cancer and 7,286 matched controls in a discovery set and 1,991 patients with cancer and 2,504 matched controls in a validation set across nine cancer types. Further, The Cancer Genome Atlas (TCGA) germline data were used to replicate the findings.

resultsWe identified 133 significant pathway-cancer pairs (85 replicated) and 90 significant gene-cancer pairs (12 replicated). In addition, we identified 18 genes and 3 pathways that were associated with survival outcome across cancers (Bonferroni

conclusionsIn this study, we identified potential predisposition genes and pathways based on rare variants in nine cancers. IMPACT: This work adds to the knowledge base and progress being made in precision medicine.

Indexed as

Genetic Predisposition to DiseaseBiological Specimen BanksBiomarkers, TumorCase-Control StudiesExome SequencingFemaleGenome-Wide Association StudyGerm-Line MutationHumansMaleNeoplasmsBiomarkers, Tumor

Identifiers

PMID34244158
PMCPMC8419143
OpenAlexW3180783768

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.